WithdrawnPhase 2NCT03933761
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
Studying Malignant mixed Müllerian tumor of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Principal Investigator
- Alison FreimundPeter MacCallum Cancer Centre, Australia
- Intervention
- Pamiparib(drug)
- Eligibility
- 18 years · FEMALE
- Timeline
- 2019 – 2021
Collaborators
BeiGene
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03933761 on ClinicalTrials.govOther trials for Malignant mixed Müllerian tumor of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06483048MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian CancerMayo Clinic
- RECRUITINGPHASE2, PHASE3NCT03651206Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibARCAGY/ GINECO GROUP
See all trials for Malignant mixed Müllerian tumor of the ovary →